Current Trials

Validated Technology
Argos’ RNA-loaded dendritic cell vaccine technology has been validated in numerous preclinical studies of tumor metastasis in animals as well as in investigator-sponsored clinical trials in humans. These studies confirm that the technology is not only safe and potent at inducing anti-tumor responses in immunized patients, but also show encouraging clinical responses in physician-sponsored small trials. These results will be validated in larger company-sponsored trials, leading in some cases to fast-track registration.

Therapeutic Areas
Metastatic Renal Cell Carcinoma
Argos’ initial total tumor RNA-loaded dendritic cell vaccine is currently in a corporate Phase I/II clinical trial at clinical sites in the United States and Canada. The trial focuses on patients with newly diagnosed metastatic renal cell carcinoma. An additional objective of the trial includes demonstrating the safety and commercial feasibility of processing dendritic cells at a central manufacturing facility with delivery of the vaccine to multiple clinical sites.

For further information and eligibility criteria, refer to the National Institutes of Health ClinicalTrials.gov website at
http://www.clinicaltrials.gov/ct/gui/show/NCT00087984?order=1

Other Cancers
Argos is conducting preclinical research in a number of additional cancers and expects to begin investigator-sponsored clinical trials using its RNA-loaded dendritic cell vaccine in one or more of these cancers in the next six to 12 months.

Other Therapeutic Areas
Argos is also conducting preclinical research in HIV and plans to begin an investigator-sponsored clinical trial using its RNA-loaded dendritic cell vaccine to treat HIV in 2005.